Cargando…
Residual C-peptide in patients with Type 1 diabetes and multiethnic backgrounds
OBJECTIVE: To evaluate serum C-peptide in 88 patients from a multiethnic population with Type-1 diabetes and variable disease durations. METHOD: Eighty-eight patients with a mean disease duration of 8.1±7.6 years were included and underwent C-peptide measurement before and after glucagon stimulation...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552451/ https://www.ncbi.nlm.nih.gov/pubmed/23420171 http://dx.doi.org/10.6061/clinics/2013(01)RC02 |
_version_ | 1782256676734238720 |
---|---|
author | de Almeida, Mirella Hansen Dantas, Joana Rodrigues Barone, Bianca Serfaty, Fabiano Marcel Kupfer, Rosane Albernaz, Marta Bencke, Maria Rocio Zajdenverg, Lenita Rodacki, Melanie de Oliveira, José Egídio Paulo |
author_facet | de Almeida, Mirella Hansen Dantas, Joana Rodrigues Barone, Bianca Serfaty, Fabiano Marcel Kupfer, Rosane Albernaz, Marta Bencke, Maria Rocio Zajdenverg, Lenita Rodacki, Melanie de Oliveira, José Egídio Paulo |
author_sort | de Almeida, Mirella Hansen |
collection | PubMed |
description | OBJECTIVE: To evaluate serum C-peptide in 88 patients from a multiethnic population with Type-1 diabetes and variable disease durations. METHOD: Eighty-eight patients with a mean disease duration of 8.1±7.6 years were included and underwent C-peptide measurement before and after glucagon stimulation. Chi-squared and Mann Whitney U-tests were used to compare the variables between groups (all two-tailed, α = 0.05). Spearmańs correlation coefficient was used to test the association between the continuous variables. Logistic regression was used for the multivariate analysis. Twenty-eight (31.8%) individuals had significantly detectable C-peptide levels after stimuli, particularly those with a shorter disease duration (p<0.001). RESULTS: Patients with detectable C-peptide levels required lower insulin doses (p<0.009) and had similar HbA1C results (p = 0.182) and fewer chronic complications (p = 0.029). CONCLUSION: C-peptide detection was common in Type-1 diabetics, particularly shortly after being diagnosed. This result may have clinical implications. |
format | Online Article Text |
id | pubmed-3552451 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo |
record_format | MEDLINE/PubMed |
spelling | pubmed-35524512013-01-28 Residual C-peptide in patients with Type 1 diabetes and multiethnic backgrounds de Almeida, Mirella Hansen Dantas, Joana Rodrigues Barone, Bianca Serfaty, Fabiano Marcel Kupfer, Rosane Albernaz, Marta Bencke, Maria Rocio Zajdenverg, Lenita Rodacki, Melanie de Oliveira, José Egídio Paulo Clinics (Sao Paulo) Rapid Communication OBJECTIVE: To evaluate serum C-peptide in 88 patients from a multiethnic population with Type-1 diabetes and variable disease durations. METHOD: Eighty-eight patients with a mean disease duration of 8.1±7.6 years were included and underwent C-peptide measurement before and after glucagon stimulation. Chi-squared and Mann Whitney U-tests were used to compare the variables between groups (all two-tailed, α = 0.05). Spearmańs correlation coefficient was used to test the association between the continuous variables. Logistic regression was used for the multivariate analysis. Twenty-eight (31.8%) individuals had significantly detectable C-peptide levels after stimuli, particularly those with a shorter disease duration (p<0.001). RESULTS: Patients with detectable C-peptide levels required lower insulin doses (p<0.009) and had similar HbA1C results (p = 0.182) and fewer chronic complications (p = 0.029). CONCLUSION: C-peptide detection was common in Type-1 diabetics, particularly shortly after being diagnosed. This result may have clinical implications. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2013-01 /pmc/articles/PMC3552451/ /pubmed/23420171 http://dx.doi.org/10.6061/clinics/2013(01)RC02 Text en Copyright © 2013 Hospital das Clínicas da FMUSP http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Rapid Communication de Almeida, Mirella Hansen Dantas, Joana Rodrigues Barone, Bianca Serfaty, Fabiano Marcel Kupfer, Rosane Albernaz, Marta Bencke, Maria Rocio Zajdenverg, Lenita Rodacki, Melanie de Oliveira, José Egídio Paulo Residual C-peptide in patients with Type 1 diabetes and multiethnic backgrounds |
title | Residual C-peptide in patients with Type 1 diabetes and multiethnic backgrounds |
title_full | Residual C-peptide in patients with Type 1 diabetes and multiethnic backgrounds |
title_fullStr | Residual C-peptide in patients with Type 1 diabetes and multiethnic backgrounds |
title_full_unstemmed | Residual C-peptide in patients with Type 1 diabetes and multiethnic backgrounds |
title_short | Residual C-peptide in patients with Type 1 diabetes and multiethnic backgrounds |
title_sort | residual c-peptide in patients with type 1 diabetes and multiethnic backgrounds |
topic | Rapid Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552451/ https://www.ncbi.nlm.nih.gov/pubmed/23420171 http://dx.doi.org/10.6061/clinics/2013(01)RC02 |
work_keys_str_mv | AT dealmeidamirellahansen residualcpeptideinpatientswithtype1diabetesandmultiethnicbackgrounds AT dantasjoanarodrigues residualcpeptideinpatientswithtype1diabetesandmultiethnicbackgrounds AT baronebianca residualcpeptideinpatientswithtype1diabetesandmultiethnicbackgrounds AT serfatyfabianomarcel residualcpeptideinpatientswithtype1diabetesandmultiethnicbackgrounds AT kupferrosane residualcpeptideinpatientswithtype1diabetesandmultiethnicbackgrounds AT albernazmarta residualcpeptideinpatientswithtype1diabetesandmultiethnicbackgrounds AT benckemariarocio residualcpeptideinpatientswithtype1diabetesandmultiethnicbackgrounds AT zajdenverglenita residualcpeptideinpatientswithtype1diabetesandmultiethnicbackgrounds AT rodackimelanie residualcpeptideinpatientswithtype1diabetesandmultiethnicbackgrounds AT deoliveirajoseegidiopaulo residualcpeptideinpatientswithtype1diabetesandmultiethnicbackgrounds |